National Virtual Biotechnology Laboratory (2020 DOE transition): Difference between revisions

National Virtual Biotechnology Laboratory (2020 DOE transition) (view source)

Revision as of 00:51, 21 December 2024

20 bytes added , 21 December 2024

CargoAdmin, Bureaucrats, Moderators (CommentStreams), fileuploaders, Interface administrators, newuser, Push subscription managers, Suppressors, Administrators

5,230

edits

@@ Line 4: / Line 4: @@
 == Summary ==
-The U.S. Department of Energy National Virtual Biotechnology Laboratory (NVBL) is a consortium of DOE National laboratories, each with core capabilities relevant to the threats posed by COVID-19. Funded by the Coronavirus Aid, Relief, and Economic Security (CARES) Act in March 2020, the NVBL is taking advantage of DOE user facilities, including light and neutron sources; nanoscale science centers; sequencing and bio- characterization facilities; and high performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying new targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks by harnessing extensive additive manufacturing capabilities. The NVBL collaborates extensively with researchers, both in academia and the private sector. In addition, the DOE user facilities are available to users in all sectors of the research community.
+The U.S. Department of Energy National Virtual Biotechnology Laboratory (NVBL) is a consortium of DOE National laboratories, each with core capabilities relevant to the threats posed by COVID-19. Funded by the [[Coronavirus Aid, Relief, and Economic Security]] (CARES) Act in March 2020, the NVBL is taking advantage of DOE user facilities, including light and neutron sources; nanoscale science centers; sequencing and bio- characterization facilities; and high performance computer facilities, to address key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying new targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks by harnessing extensive additive manufacturing capabilities. The NVBL collaborates extensively with researchers, both in academia and the private sector. In addition, the DOE user facilities are available to users in all sectors of the research community.
 == Issue(s) ==
@@ Line 11: / Line 11: @@
 With an extraordinary amount of bioscience and biotechnology expertise distributed across the 17 DOE laboratories, but with a need to focus research efforts against COVID-19 as one team, DOE and the laboratories launched the NVBL.
-The NVBL framework provides DOE with a standing mechanism to i.) quickly assess R&D needs associated with a rapidly evolving situation; ii.) identify critical capabilities existing within the national laboratory system, DOE user facilities, and DOE’s broader research enterprise; iii.) develop a multi-program and multi-institutional plan to deploy DOE’s unique capabilities; and iv.) coordinate efforts with other Federal agencies, state and local representatives, and partners in industry.
+The NVBL framework provides DOE with a standing mechanism to
+* i.) quickly assess R&D needs associated with a rapidly evolving situation;
+* ii.) identify critical capabilities existing within the national laboratory system, DOE user facilities, and DOE’s broader research enterprise;
+* iii.) develop a multi-program and multi-institutional plan to deploy DOE’s unique capabilities; and
+* iv.) coordinate efforts with other Federal agencies, state and local representatives, and partners in industry
 Institutionalizing the NVBL framework within Office of Science (SC) programs will enable DOE to respond to future shifts in federal priorities or emerging opportunities, including future national crisis situations, in the broader S&T landscape.
@@ Line 42: / Line 47: @@
 == Background ==
-DOE’s rapid research response to COVID builds on the Department’s participation in the National Biodefense Strategy (released September 2018). The Secretary of Energy is a member of the interagency Biodefense Steering Committee, which is responsible for the federal government’s awareness of, preparation for, response to, and recovery from bioincidents. The Office of Science maintains a part-time representative at HHS to take part in the Biodefense Coordination Team, which carries out the policy requirements of the Strategy.
+DOE’s rapid research response to COVID builds on the Department’s participation in the National Biodefense Strategy (released September 2018). The Secretary of Energy is a member of the interagency Biodefense Steering Committee, which is responsible for the federal government’s awareness of, preparation for, response to, and recovery from bioincidents. The [[Office of Science]] maintains a part-time representative at HHS to take part in the Biodefense Coordination Team, which carries out the policy requirements of the Strategy.
 When the COVID-19 public health emergency was announced, the Secretary named the Director, Office of Science (SC-1), to be responsible for DOE research response and the creation of the Coronavirus R&D Task Team (CRDTT), a cross- DOE team that met weekly until summer 2020. One of SC-1’s first activities was to release a Dear Colleague Letter to the scientific community asking for avenues of research that should be prioritized, and that fall under DOE’s broad purview and do not include human health research.